Peritoneal Cancer (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer – Drugs In Development, 2021, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 25, 100, 75, 2, 21, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 8 and 1 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AB Science SA

AbbVie Inc

Advenchen Laboratories LLC

AIM ImmunoTech Inc

AiVita Biomedical Inc

Akeso Inc

Aldeyra Therapeutics Inc

ALX Oncology Holdings Inc

Amgen Inc

Anew Oncology Inc

Apexigen Inc

APIM Therapeutics AS

Apollomics Inc

Aprea Therapeutics Inc

Aravive Inc

Arch Oncology Inc

Arrien Pharmaceuticals LLC

Artios Pharma Ltd

Ascend Biopharmaceuticals Ltd

Ascenta Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Peritoneal Cancer - Overview

Peritoneal Cancer - Therapeutics Development

Peritoneal Cancer - Therapeutics Assessment

Peritoneal Cancer - Companies Involved in Therapeutics Development

Peritoneal Cancer - Drug Profiles

Peritoneal Cancer - Dormant Projects

Peritoneal Cancer - Discontinued Products

Peritoneal Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Peritoneal Cancer, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Peritoneal Cancer – Pipeline by AB Science SA, 2021

Peritoneal Cancer – Pipeline by AbbVie Inc, 2021

Peritoneal Cancer – Pipeline by Advenchen Laboratories LLC, 2021

Peritoneal Cancer – Pipeline by AIM ImmunoTech Inc, 2021

Peritoneal Cancer – Pipeline by AiVita Biomedical Inc, 2021

Peritoneal Cancer – Pipeline by Akeso Inc, 2021

Peritoneal Cancer – Pipeline by Aldeyra Therapeutics Inc, 2021

Peritoneal Cancer – Pipeline by Aston Sci Co Ltd, 2021

Peritoneal Cancer – Pipeline by Corcept Therapeutics Inc, 2021

Peritoneal Cancer – Dormant Projects, 2021

Peritoneal Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Peritoneal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports